---
title: Liver decompensation after rapid weight loss from semaglutide in a patient
  with non-alcoholic steatohepatitis -associated cirrhosis
date: '2024-01-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38186682/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240108170815&v=2.18.0
source: heidelberg[Affiliation]
description: There is rapidly increasing uptake of GLP-1 (glucagon-like peptide-1)
  agonists such as semaglutide worldwide for weight loss and management of non-alcoholic
  steatohepatitis (NASH). remains a paucity of safety data in the vulnerable NASH
  cirrhotic population. We report herein the first documented case of liver decompensation
  and need for liver transplant waitlisting in a patient with NASH-cirrhosis treated
  with semaglutide. Rapid weight loss led to the development of ascites and ...
disable_comments: true
---
There is rapidly increasing uptake of GLP-1 (glucagon-like peptide-1) agonists such as semaglutide worldwide for weight loss and management of non-alcoholic steatohepatitis (NASH). remains a paucity of safety data in the vulnerable NASH cirrhotic population. We report herein the first documented case of liver decompensation and need for liver transplant waitlisting in a patient with NASH-cirrhosis treated with semaglutide. Rapid weight loss led to the development of ascites and ...